News & Updates

Individuals with worsening chronic kidney disease (CKD) are at greater risk for emergently treated hypocalcemia with denosumab, and the highest risk is observed among dialysis-dependent (DD) patients and those with CKD–mineral and bone disorder (CKD-MBD), reveals a study.

The COVID-19 pandemic had a negative impact on blood pressure (BP) control, as shown in a study using ambulatory BP monitoring (ABPM).

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis who are taking antihypertensive medications, including calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), are at increased risk of developing hepatocellular carcinoma (HCC), suggests a study.